Capri Holdings Ltd vs ResMed Inc. — how do they compare? Capri Holdings Ltd trades at $15.49 (market cap $1.75B), while ResMed Inc. trades at $225.22 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 18.6× Capri Holdings Ltd's market cap, and ResMed Inc. pays a 1.17% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| CPRI | RMD | |
|---|---|---|
Market Cap | $1.75B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $293.73 |
52-Week Low | $14.98 | $182.82 |
Enterprise Value | $3.03B | $31.97B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
Capri Holdings (CPRI) trades at $15.47, near its 52-week low, with a bearish technical outlook and recent earnings beats overshadowed by declining revenue and a net loss of $1.18 billion in 2025. The company faces challenges in its core Michael Kors brand, with revenue forecasts cut and a high debt-to-asset ratio of 28.79% as of 2025. Despite a consensus price target of $19.60, analyst sentiment is mixed, with 44% buy ratings but significant hold recommendations.
The stock's investment appeal hinges on a successful turnaround, with potential upside from margin improvements and Jimmy Choo growth, but risks include persistent revenue declines, luxury market softness, and execution uncertainties. Near-term volatility is likely as the company navigates brand revamps and inventory issues.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Trailing returns across standard periods
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →